Static Graviceptive Functions in Patients With Cervical Dystonia (CD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01180270 |
Recruitment Status :
Completed
First Posted : August 12, 2010
Last Update Posted : January 31, 2012
|
Tracking Information | |||
---|---|---|---|
First Submitted Date | July 14, 2010 | ||
First Posted Date | August 12, 2010 | ||
Last Update Posted Date | January 31, 2012 | ||
Study Start Date | June 2010 | ||
Actual Primary Completion Date | January 2012 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures |
|
||
Original Primary Outcome Measures | Same as current | ||
Change History | |||
Current Secondary Outcome Measures |
|
||
Original Secondary Outcome Measures | Same as current | ||
Current Other Pre-specified Outcome Measures | Not Provided | ||
Original Other Pre-specified Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title | Static Graviceptive Functions in Patients With Cervical Dystonia (CD) | ||
Official Title | Experimental Pilot Trial Assessing Static Graviceptive Function in Patients With Cervical Dystonia | ||
Brief Summary | The purpose of this experimental pilot study is to test the effect of normalization of the head position on the sense of balance at patients with cervical dystonia under routine botulinum toxin treatment. | ||
Detailed Description | Background: The pathophysiological mechanism of cervical dystonia remains unclear. Affection of static graviceptive function has been shown in these patients by measuring the Subjective Visual Vertical (SVV). Healthy subjects, tested with voluntary head tilt, would tilt SVV in the opposite direction of the head. (Müller "E" effect), whereas patients with cervical dystonia set SVV close to true upright with a minimal deviation toward head-tilt. The mechanism of this change in otolith activity in patients with cervical dystonia is still unknown. When treated with botulinum toxin, head deviation will be reversed during a period of approximate 6-9 weeks, with a first peak of action after approximate 3 weeks. Aim The aim of this study is to investigate the effect of normalization of the head position under routine intramuscular botulinum toxin application in the cervical muscles (screening, 3 weeks and 9 weeks after injection) on static graviceptive function in patients with cervical dystonia. Rationale To our knowledge, the effect of botulinum toxin therapy on static otolith function in patients with cervical dystonia has never been evaluated. This study may provide new informations on the neural plasticity of the vestibular system and may contribute to the understanding of pathophysiological mechanisms of cervical dystonia. Accordingly, it may help developing new treatment strategies for this disease. Primary hypothesis There is a difference of at least 6 degrees in subjective visual vertical of patients with CD tested in habitual head position at study inclusion and 3 weeks after injection of Botulinum Toxin. Study design Subjective visual vertical will be tested in Patients with CD, who are pre-treated with botulinum toxin and show a good treatment response. Patients SVV will be assessed before routine botulinum toxin injection (on day of injection), 3 and 9 weeks after injection. For control, SVV will be assessed in normal subjects. SVV assessment SVV will be performed by the patient and control while sitting upright in a dark room in different head positions, the head is fixed using a head holder. In CD patients, SVV will be assessed in different head positions:
SVV in normal subject, with A) head fixed in neutral position (defined as 0° or no head rotation), B) ear deviated 30° to the left, C) ear deviated 30° to the right, D) ear deviated 15° to the left, E) ear deviated 15° to the right, will be assessed. |
||
Study Type | Observational | ||
Study Design | Time Perspective: Prospective | ||
Target Follow-Up Duration | Not Provided | ||
Biospecimen | Not Provided | ||
Sampling Method | Non-Probability Sample | ||
Study Population | outpatient botulinum toxin clinic of the department of neurology, medical university of Vienna healthy subjects, residents of vienna | ||
Condition | Cervical Dystonia | ||
Intervention | Not Provided | ||
Study Groups/Cohorts |
|
||
Publications * |
|
||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status | Completed | ||
Actual Enrollment |
45 | ||
Original Estimated Enrollment |
10 | ||
Actual Study Completion Date | January 2012 | ||
Actual Primary Completion Date | January 2012 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: Patients and Control
Patients
|
||
Sex/Gender |
|
||
Ages | 18 Years to 80 Years (Adult, Older Adult) | ||
Accepts Healthy Volunteers | Yes | ||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries | Austria | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number | NCT01180270 | ||
Other Study ID Numbers | SVV_CD1 | ||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Responsible Party | Kirsten Elwischger, Medical University of Vienna | ||
Study Sponsor | Kirsten Elwischger | ||
Collaborators | Not Provided | ||
Investigators | Not Provided | ||
PRS Account | Medical University of Vienna | ||
Verification Date | January 2012 |